arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

GRAIL, Inc.

GRAL
$69.45 ▲ +6.12 (+9.66%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
14 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

GRAIL, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.8B
Dividend Yield
Revenue Growth 28.1%
Op. Margin -332.9%
ROIC -4.0%
FCF / Share $-2.15
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.78M
↑ +28.1%
Net Income Profit after all expenses
$-93.19M
↑ +12.3%
Operating Margin Operating profit as % of sales
-332.9%
↓ -16.7% 0th
FCF / Share Free cash flow per share
$-2.15
↑ +22.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
30
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 14 quarters